GRIFOLS SA-ADR (GRFS)

US3984384087 - ADR

7.005  +0.06 (+0.94%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GRIFOLS SA-ADR

NASDAQ:GRFS (5/10/2024, 2:13:17 PM)

7.005

+0.06 (+0.94%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.76B
Shares
PE70.05
Fwd PE7.36
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GRFS Daily chart

Company Profile

Grifols SA engages in the production of plasma derivatives. The company is headquartered in Barcelona, Barcelona and currently employs 23,245 full-time employees. The company went IPO on 2006-05-17. The company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Company Info

GRIFOLS SA-ADR

C/ Jesus y Maria, 6

Barcelona BARCELONA 08174

P: 34935710000

CEO: Raimon Grifols Roura

Employees: 23245

Website: https://www.grifols.com/

GRFS News

News Image21 days ago - GrifolsGrifols 2023 Annual Report on Form 20-F filed with the SEC

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

News Image22 days ago - Grifols, S.A.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the...

News Imagea month ago - Grifols, S.A.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a...

News Imagea month ago - Grifols, S.A.Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE

Le test d’acide nucléique in vitro de Grifols détecte quatre types d’arbovirus, contribuant ainsi à la diminution du risque d’infections transmises par...

News Imagea month ago - Grifols, S.A.Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren

Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu...

News Imagea month ago - Grifols, S.A.Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE

Il test NAT in vitro di Grifols rileva quattro tipi di arbovirus, contribuendo a ridurre il rischio di infezioni trasmesse tramite trasfusioneGli arbovirus...

GRFS Twits

Here you can normally see the latest stock twits on GRFS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example